Our studies are aimed at evaluating whether gene therapy with replication- deficient, recombinant adenovirus vectors can be used to prevent and treat restenosis after angioplasty and to induce angiogenesis to restore blood supply to ischemic tissues. For the studies on angiogenesis, we have constructed adenoviral vectors which carry the cDNA for the following angiogenic growth factors: (1) Vascular endothelial growth factor (VEGF), (2) Acidic fibroblast growth factor (aFGF), (3) A recombinant form of aFGF which modified by the addition of the secretory signal sequence from FGF-4 (sp-aFGF), (4) Basic FGF(bFGF), (5) A recombinant form of bFGF which was modified by the addition of the secretory signal sequence form FGF-4, and (6) platelet-derived endothelial cell growth factor (PD-ECGF). For the studies on restenosis after angioplasty, we plan to use adenoviral vectors which carry the cDNA for the following proteins: 1) VEGF and PD-ECGF. These viral vectors may enhance reendoth elialization at the site of endovascular injury and decrease the severity of intimal hyperplasia by this mechanism. (2) p53, apoptosis. The following studies have been implemented as part of this study. Studies in vitro have shown that the above adenovirus vectors make functional proteins and modulate cell growth. In experiments in vivo we have shown that the adenovirus vectors which carry the cDNA either for aFGF for the secreted form of aFGF induce angiogenesis in vivo when coinjected with Matrigel, subcutaneously in mice. Since persistent expression of growth factors may have a tumorigenic potential we have examined the biosafety of the adenovirus vectors which carry the cDNA for acidic FGF and for the secreted form of acidic FGF. Our in vivo studies with nude mice show that these vectors do not cause tumor formation. We examined the safety and efficacy of gene transfer into minipig heart either with the intramyocardial (IM) or intracoronary (IC) injection of adCMV.NLSbeta-gal. IM injection was more effective than IC infusion in targeting cell transduction to a well-defined area of myocardium. Followin IM injection exogenous gene expression peaked at 2-4 days and returned to control value within one month. No minipigs died and by epicardial echocardiography there was no evidence of either segmental or global left ventricular dysfunction. Thus, Ad vectors appear safe and effective for gene transfer into the myocardium of large mammals. 5) Experiments on restenosis have been aimed at developing a rat model of intimal hyperplasia after carotid artery injury and minipig model of coronary intimal hyperplasia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Intramural Research (Z01)
Project #
1Z01AG000811-02
Application #
3745552
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
National Institute on Aging
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Wei, Lei; Kanbe, Katsuaki; Lee, Mark et al. (2010) Stimulation of chondrocyte hypertrophy by chemokine stromal cell-derived factor 1 in the chondro-osseous junction during endochondral bone formation. Dev Biol 341:236-45
Ahmet, Ismail; Morrell, Chris; Lakatta, Edward G et al. (2009) Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 331:178-85
Fedorova, Olga V; Zhuravin, Igor A; Agalakova, Natalia I et al. (2007) Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor. J Hypertens 25:1834-44
Moon, Chanil; Krawczyk, Melissa; Paik, Doojin et al. (2006) Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316:999-1005
Moon, Chanil; Krawczyk, Melissa; Lakatta, Edward G et al. (2006) Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats. Cardiovasc Drugs Ther 20:245-51
Ahmet, Ismayil; Lakatta, Edward G; Talan, Mark I (2005) Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 10:289-96
Moon, Chanil; Krawczyk, Melissa; Paik, Doojin et al. (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 19:243-50
Ravi, Luke B; Poosala, Suresh; Ahn, Dongchoon et al. (2005) Red cell interactions with amyloid-beta(1-40) fibrils in a murine model. Neurobiol Dis 19:28-37
Ahmet, Ismayil; Wan, Ruiqian; Mattson, Mark P et al. (2005) Cardioprotection by intermittent fasting in rats. Circulation 112:3115-21
Fedorova, Olga V; Agalakova, Natalia I; Talan, Mark I et al. (2005) Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats. J Hypertens 23:1515-23

Showing the most recent 10 out of 18 publications